This refresh
Data-driven refresh June 22, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow), ranked across a 5214-ticker universe covering every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (2547 passed the market-cap / liquidity screen; financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. INCY — Incyte Corporation · score 90.8
Biotechnology · price $98.22 · 1Y $109.35 · 5Y $160.10 · 10Y $237.49
FCF $1.4b C+ · Rev +21.2% A- · D/E 0.01 A · P/E 13.9x A- · PEG 0.36 A
Why now. Incyte Corporation is a compelling growth investment due to its ability to compound earnings through its high-margin biotechnology business, with a 26.7% profit margin, 21.2% revenue growth, and a 0.36 PEG ratio, indicating the stock is reasonably priced given its growth prospects. The company's strong financials, including $1.4b in free cash flow, support its growth trajectory. The bull case rests on the company's ability to maintain its high revenue growth rate.
Moat. Incyte's durable competitive advantage stems from its high return on equity of 25.5%, driven by its pricing power in the biotechnology sector. The company's low debt-to-equity ratio of 0.01 and significant free cash flow also contribute to its moat, allowing it to invest in research and development and maintain its competitive position. This advantage is difficult for competitors to replicate quickly, given the complexity and cost of developing new biotechnology products.
Risk. The primary risk to Incyte's growth trajectory is a decline in its revenue growth rate, potentially driven by increased competition in the biotechnology sector. If the company's revenue growth slows significantly, its valuation multiple could contract, leading to a decline in the stock price. A 13.9 P/E ratio and 0.79 beta indicate that the stock may be sensitive to changes in growth expectations. The bear case would be confirmed if Incyte's revenue growth rate were to slow dramatically, leading to a re-rating of the stock.
Horizon. 1-3 yr $109.35 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $160.10 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $237.49 if current growth sustains into durable earnings power.
2. DOCS — Doximity, Inc. · score 90.1
Health Information Services · price $20.46 · 1Y $25.42 · 5Y $37.22 · 10Y $55.21
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 20.9x B+ · PEG 0.59 A-
Why now. Doximity's high-quality compounder status is driven by its strong 30.4% profit margin and 20.6% ROE, which are fueled by its 13.1% revenue growth. This growth, combined with a 0.59 PEG ratio, indicates that the company's expansion is likely to persist. The crux of this thesis rests on the company's ability to maintain its high profit margins, which will be crucial for sustaining its growth trajectory.
Moat. Doximity's durable edge is rooted in its high 20.6% ROE, which is attributed to its pricing power in the health information services sector. This pricing power is a result of the company's strong position in its market, allowing it to maintain high margins. Additionally, the company's low 0.01 debt-to-equity ratio provides it with the financial flexibility to invest in its business and further solidify its competitive position.
Risk. The strongest argument against Doximity is the potential for its high 20.9 P/E ratio to contract, particularly if the company's revenue growth slows. If Doximity's growth decelerates, its valuation multiple may decrease, leading to a decline in the stock price. A concrete signal that would confirm this bear case would be a significant decline in the company's revenue growth rate, which would indicate that the company's high valuation is no longer justified.
Horizon. 1-3 yr $25.42 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $37.22 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $55.21 if current growth sustains into durable earnings power.
3. ADBE — Adobe Inc. · score 89.7
Software - Application · price $195.16 · 1Y $282.27 · 5Y $413.27 · 10Y $613.06
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 11.2x A · PEG 0.53 A-
Why now. Adobe's 10.5% revenue growth rate, combined with a 28.7% profit margin and $10.3B in free cash flow, positions the company for sustained compounding, driven by its high-quality growth profile. This growth persists due to the company's ability to maintain a 11.2 P/E ratio, indicating a reasonable valuation. The crux of this thesis rests on Adobe's ability to continue delivering strong revenue growth while maintaining its profit margins.
Moat. Adobe's durable edge is protected by its 62.8% return on equity, driven by pricing power from its category leadership in the software application sector. This pricing power is attributed to the company's strong position in the market, allowing it to maintain high profit margins. Additionally, the company's 3.1 price-to-sales ratio indicates a reasonable valuation, making it difficult for competitors to quickly replicate Adobe's business model.
Risk. The strongest argument against Adobe is the potential for decelerating growth, driven by increasing competition in the software application sector. With a 1.4 beta, the company's stock price is highly sensitive to market fluctuations, and a 0.61 debt-to-equity ratio indicates a moderate level of debt. If Adobe's revenue growth rate were to slow significantly, it could confirm the bear case and break the bull thesis.
Horizon. 1-3 yr $282.27 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $413.27 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $613.06 if current growth sustains into durable earnings power.
4. HRMY — Harmony Biosciences Holdings, Inc. · score 89.7
Biotechnology · price $33.28 · 1Y $44.36 · 5Y $64.95 · 10Y $96.35
1Y +4% C+ · Rev +21.5% A- · ROE 16.0% B+ · FCF $342m C
Why now. Harmony Biosciences presents a compelling growth-at-a-reasonable-price opportunity, with its core biotechnology product driving robust top-line expansion. The company boasts an impressive 21.5% FY YoY revenue growth, yet trades at a modest 13.4 P/E TTM, generating substantial $342m in TTM free cash flow. This strong cash generation, coupled with its growth trajectory, positions HRMY for sustained compounding as it reinvests in its specialized therapeutic pipeline.
Moat. Harmony Biosciences' durable edge in the biotechnology sector is rooted in its intellectual property protecting its specialized therapeutic offerings, which are critical in their niche market. The significant regulatory hurdles and development costs inherent in bringing new biotechnology products to market create substantial barriers to entry, effectively insulating HRMY from rapid competition. This allows the company to maintain a healthy 16.2% profit margin and a strong 16% return on equity, reflecting its protected market position.
Risk. The primary bear case for Harmony Biosciences centers on the inherent pipeline risk and potential for competitive disruption common in the biotechnology sector. While current revenue growth is strong, a failure in a key clinical trial or the emergence of a superior substitute therapy from a larger competitor could significantly decelerate future growth. A sustained drop in the company's 21.5% FY YoY revenue growth rate, particularly if accompanied by a contraction in its 16.2% profit margin, would confirm the bear's skepticism regarding its long-term market position.
Horizon. 1-3 yr $44.36 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $64.95 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $96.35 if current growth sustains into durable earnings power.
5. INTU — Intuit Inc. · score 89.5
Software - Application · price $267.00 · 1Y $488.17 · 5Y $714.73 · 10Y $1,060
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 16.3x A- · PEG 0.69 A-
Why now. Intuit is a compelling growth compounder, demonstrating persistent revenue expansion at 15.6% FY YoY, fueled by its dominant position in the Software - Application sector. This growth translates directly into exceptional free cash flow generation of $7.8b TTM, which, against a $73.0b market cap, makes its 16.3 P/E and 0.69 PEG ratio remarkably attractive for a business of this quality. The crux is the company's ability to sustain this high-margin revenue growth while converting it into significant shareholder returns.
Moat. Intuit's enduring moat stems from the mission-critical nature of its software applications, which embed deeply into customer workflows, creating high switching costs for businesses and individuals. This structural advantage allows for significant pricing power and operational efficiency, evidenced by its robust 22.2% Return on Equity and 21.9% profit margin. Competitors face an uphill battle dislodging established solutions that are integral to financial operations.
Risk. The primary bear case for Intuit centers on potential market saturation within its core Software - Application segments, leading to decelerating growth and increased competitive pressure. The stock's dramatic fall from its 52-week high of $813.7 to its current price of $267, hovering near its 52-week low of $259.23, suggests investors are already pricing in significant headwinds or a fundamental shift. A sustained decline in the current 15.6% revenue growth rate would confirm the bear's thesis, indicating a loss of market momentum.
Horizon. 1-3 yr $488.17 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $714.73 at ~22% CAGR — compounding case rests on the competitive position widening. 10 yr $1,060 if current growth sustains into durable earnings power.
6. LRN — Stride, Inc. · score 89.3
Education & Training Services · price $82.80 · 1Y $95.22 · 5Y $139.41 · 10Y $206.81
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 13.0x A- · PEG 0.47 A
Why now. Stride, Inc. presents an exceptional growth opportunity disguised by its valuation, trading at a compelling P/E of 13 and an even more attractive PEG ratio of 0.47 despite robust 17.9% FY YoY revenue growth. This deep undervaluation in the expanding Education & Training Services sector, coupled with $414m in TTM FCF, provides a strong foundation for sustained compounding. The crux of the thesis rests on the market re-rating LRN to reflect its true growth potential and efficient capital allocation.
Moat. Stride's durable edge in the Education & Training Services sector is built on its extensive infrastructure and proprietary curriculum development, which create significant switching costs for both institutional clients and individual learners. Its robust 18.8% ROE demonstrates efficient capital deployment and the operational leverage achieved from scaling its comprehensive online learning platforms. This established ecosystem and deep integration make it challenging for competitors to quickly replicate Stride's market position and offerings.
Risk. The primary bear case for LRN centers on potential market saturation or intensifying competition within the online Education & Training Services sector, which could significantly temper its current growth trajectory. While current revenue growth is 17.9%, a sustained deceleration, particularly given its low beta of 0.08, suggests the market may be underestimating future competitive pressures. A concrete signal confirming the bear case would be two consecutive quarters of revenue growth falling below 10%, indicating a fundamental shift in market dynamics.
Horizon. 1-3 yr $95.22 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $139.41 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $206.81 if current growth sustains into durable earnings power.
7. ADMA — ADMA Biologics, Inc. · score 89.2
Biotechnology · price $8.31 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
1Y -53% D · Rev +19.6% B+ · ROE 42.4% A · FCF $108m C
Why now. Biotechnology · market cap $1.9b. Down 59% from 52-week high of $20.46 — deep drawdown territory. Revenue growing +20%, comfortably above the S&P median. 5 sell-side analysts rate this a Buy with a mean 1-yr target of $17.60 (implying +112% upside).
Moat. Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk. Down 59% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~25% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
8. PCTY — Paylocity Holding Corporation · score 89.2
Software - Application · price $101.06 · 1Y $154.16 · 5Y $225.70 · 10Y $334.81
FCF $487m C · Rev +14.8% B+ · D/E 0.11 B+ · P/E 21.6x B+ · PEG 0.80 A-
Why now. Paylocity is a compelling growth compounder, demonstrating efficient expansion within the sticky Software - Application sector. Its robust 14.8% revenue growth is paired with exceptional profitability, evidenced by a 16.1% profit margin and $487m in free cash flow, translating to a strong FCF yield for a growth company. The market significantly undervalues this combination, with a PEG ratio of just 0.8, indicating its earnings growth is not fully priced in, suggesting persistent compounding from its recurring revenue model.
Moat. Paylocity's durable moat stems from the high switching costs inherent in its Software - Application offerings, particularly in critical functions like payroll and HR. Once integrated, changing providers is costly and disruptive for businesses, ensuring sticky customer relationships and recurring revenue streams. This strong customer retention and pricing power from category leadership contribute directly to its impressive 21.9% Return on Equity.
Risk. The primary bear argument centers on the potential for decelerating growth in a competitive Software - Application market, especially given the company's significant drop from its $197.78 52-week high. While 14.8% revenue growth is solid, a sustained slowdown below this rate, driven by increased competition from larger, more diversified players or new entrants, would challenge the "growth" classification. A consistent trend of declining revenue growth rates in subsequent quarters would confirm the bear thesis, indicating a maturing business facing tougher market penetration.
Horizon. 1-3 yr $154.16 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $225.70 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $334.81 if current growth sustains into durable earnings power.
9. NUTX — Nutex Health Inc. · score 87.1
Medical Care Facilities · price $150.51 · 1Y $235.50 · 5Y $344.80 · 10Y $511.48
1Y +29% B+ · Rev +82.4% A · ROE 27.8% A- · FCF $269m C
Why now. Medical Care Facilities · market cap $1.0b. Down 22% from 52-week high of $193.07 — deep drawdown territory. Revenue growing +82% — in hypergrowth territory. 4 sell-side analysts publish a mean 1-yr target of $235.50 (implying +56% upside).
Moat. ROE 28% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk. Beta 2.06 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $235.50 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $344.80 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $511.48 if current growth sustains into durable earnings power.
10. EXLS — ExlService Holdings, Inc. · score 86.1
Information Technology Services · price $25.93 · 1Y $41.75 · 5Y $52.71 · 10Y $67.60
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 16.5x A- · PEG 0.83 B+
Why now. Information Technology Services · market cap $4.0b. Down 45% from 52-week high of $47.11 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.83 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $41.75 (implying +61% upside).
Moat. ROE 32% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 118% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 45% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — multiple re-rating thesis requires a catalyst. 5 yr $52.71 at ~15% CAGR — dividend + buyback compounding. 10 yr $67.60 if the moat survives secular pressure.
11. NVDA — NVIDIA Corporation · score 86
Semiconductors · price $210.69 · 1Y $298.93 · 5Y $437.67 · 10Y $649.25
1Y +46% A- · Rev +65.5% A · ROE >100% A · FCF $119.1b A
Why now. Semiconductors · market cap $5.1T. 11% off the 52-week high of $236.54. Revenue growing +65% — in hypergrowth territory. PEG 0.65 — paying under fair value for the growth rate. 59 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $298.93 (implying +42% upside).
Moat. Net margin 63% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 82% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $5.1T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Beta 2.20 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 32x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 20.1x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Horizon. 1-3 yr $298.93 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $437.67 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $649.25 if current growth sustains into durable earnings power.
12. FISV — Fiserv, Inc. · score 85.3
Sector n/a · price $47.86 · 1Y $70.00 · 5Y $88.37 · 10Y $113.34
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.1x A- · PEG n/a
Why now. Sector n/a · market cap $25.5b. Down 73% from 52-week high of $177.36 — deep drawdown territory. 26 sell-side analysts rate this a Hold with a mean 1-yr target of $70.00 (implying +46% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 73% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $70.00 (analyst consensus (n=26)) — multiple re-rating thesis requires a catalyst. 5 yr $88.37 at ~13% CAGR — dividend + buyback compounding. 10 yr $113.34 if the moat survives secular pressure.
13. CARG — CarGurus, Inc. · score 85.2
Auto & Truck Dealerships · price $30.02 · 1Y $37.38 · 5Y $47.20 · 10Y $60.53
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 15.8x B+ · PEG 0.91 B+
Why now. Auto & Truck Dealerships · market cap $2.7b. Down 24% from 52-week high of $39.42 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.91 — paying under fair value for the growth rate. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $37.38 (implying +25% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 63% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — multiple re-rating thesis requires a catalyst. 5 yr $47.20 at ~9% CAGR — dividend + buyback compounding. 10 yr $60.53 if the moat survives secular pressure.
14. IT — Gartner, Inc. · score 84.4
Information Technology Services · price $127.49 · 1Y $166.54 · 5Y $210.25 · 10Y $269.64
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 12.6x A- · PEG 0.52 A-
Why now. Information Technology Services · market cap $8.5b. Down 69% from 52-week high of $409.76 — deep drawdown territory. PEG 0.52 — paying under fair value for the growth rate. 13 sell-side analysts rate this a Hold with a mean 1-yr target of $166.54 (implying +31% upside).
Moat. FCF converts 170% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 69% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $166.54 (analyst consensus (n=13)) — multiple re-rating thesis requires a catalyst. 5 yr $210.25 at ~11% CAGR — dividend + buyback compounding. 10 yr $269.64 if the moat survives secular pressure.
15. EPAM — EPAM Systems, Inc. · score 83.9
Information Technology Services · price $76.64 · 1Y $144.06 · 5Y $181.87 · 10Y $233.24
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 11.0x A · PEG 0.39 A
Why now. Information Technology Services · market cap $4.0b. Down 66% from 52-week high of $222.53 — deep drawdown territory. Revenue growing +15%, comfortably above the S&P median. PEG 0.39 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Buy with a mean 1-yr target of $144.06 (implying +88% upside).
Moat. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 66% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $144.06 (analyst consensus (n=18)) — multiple re-rating thesis requires a catalyst. 5 yr $181.87 at ~19% CAGR — dividend + buyback compounding. 10 yr $233.24 if the moat survives secular pressure.
16. VEEV — Veeva Systems Inc. · score 83.5
Health Information Services · price $153.30 · 1Y $245.48 · 5Y $309.91 · 10Y $397.46
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 27.2x B · PEG 0.69 A-
Why now. Health Information Services · market cap $24.9b. Down 51% from 52-week high of $310.50 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. PEG 0.69 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Buy with a mean 1-yr target of $245.48 (implying +60% upside).
Moat. Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 177% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 51% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $245.48 (analyst consensus (n=27)) — multiple re-rating thesis requires a catalyst. 5 yr $309.91 at ~15% CAGR — dividend + buyback compounding. 10 yr $397.46 if the moat survives secular pressure.
17. RMD — ResMed Inc. · score 82.6
Medical Instruments & Supplies · price $188.63 · 1Y $262.20 · 5Y $383.89 · 10Y $569.47
1Y -26% D · Rev +9.8% B · ROE 23.4% A- · FCF $1.8b C+
Why now. Medical Instruments & Supplies · market cap $27.4b. Down 36% from 52-week high of $293.81 — deep drawdown territory. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $262.20 (implying +39% upside).
Moat. Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 23% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 36% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $262.20 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $383.89 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $569.47 if current growth sustains into durable earnings power.
18. YELP — Yelp Inc. · score 82.4
Internet Content & Information · price $22.88 · 1Y $26.50 · 5Y $33.46 · 10Y $42.91
FCF $281m C · Rev +3.7% C+ · D/E 0.25 A- · P/E 10.5x A- · PEG 0.57 A-
Why now. Internet Content & Information · market cap $1.3b. Down 36% from 52-week high of $35.99 — deep drawdown territory. PEG 0.57 — paying under fair value for the growth rate. 8 sell-side analysts publish a mean 1-yr target of $26.50 (implying +16% upside).
Moat. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk. Down 36% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $26.50 (analyst consensus (n=8)) — multiple re-rating thesis requires a catalyst. 5 yr $33.46 at ~8% CAGR — dividend + buyback compounding. 10 yr $42.91 if the moat survives secular pressure.
19. DXCM — DexCom, Inc. · score 82.1
Medical Devices · price $72.47 · 1Y $85.21 · 5Y $124.75 · 10Y $185.06
1Y -9% C · Rev +15.6% B+ · ROE 31.5% A · FCF $1.4b C+
Why now. Medical Devices · market cap $28.0b. 19% off the 52-week high of $89.98. Revenue growing +16%, comfortably above the S&P median. 24 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $85.21 (implying +18% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 31% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 154% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Beta 1.44 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 31x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $85.21 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $124.75 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $185.06 if current growth sustains into durable earnings power.
20. META — Meta Platforms, Inc. · score 82.1
Internet Content & Information · price $577.22 · 1Y $827.32 · 5Y $1,044 · 10Y $1,340
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 21.0x B · PEG 0.83 B+
Why now. Internet Content & Information · market cap $1.5T. Down 28% from 52-week high of $796.25 — deep drawdown territory. Revenue growing +22%, comfortably above the S&P median. PEG 0.83 — paying under fair value for the growth rate. 59 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $827.32 (implying +43% upside).
Moat. Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.5T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $827.32 (analyst consensus (n=59)) — multiple re-rating thesis requires a catalyst. 5 yr $1,044 at ~13% CAGR — dividend + buyback compounding. 10 yr $1,340 if the moat survives secular pressure.
21. CVSA — Covista Inc. · score 82
Education & Training Services · price $119.07 · 1Y $156.25 · 5Y $197.26 · 10Y $252.98
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 17.3x B+ · PEG 0.88 B+
Why now. Education & Training Services · market cap $4.1b. Down 24% from 52-week high of $156.26 — deep drawdown territory. Revenue growing +13%, comfortably above the S&P median. PEG 0.88 — paying under fair value for the growth rate. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $156.25 (implying +31% upside).
Moat. Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 144% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — multiple re-rating thesis requires a catalyst. 5 yr $197.26 at ~11% CAGR — dividend + buyback compounding. 10 yr $252.98 if the moat survives secular pressure.
22. MELI — MercadoLibre, Inc. · score 82
Internet Retail · price $1635.15 · 1Y $2,217 · 5Y $3,246 · 10Y $4,815
1Y -33% D · Rev +34.3% A · ROE 26.4% A- · FCF $11.8b A-
Why now. Internet Retail · market cap $82.9b. Down 38% from 52-week high of $2645.22 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $2,217 (implying +36% upside).
Moat. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $82.9b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 38% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 43x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. E-commerce competition — Amazon, Walmart, Shein, and Temu have each forced the rest of the category to compete on price, fulfillment speed, or assortment; sustaining margins requires one of those being structurally defended.
Horizon. 1-3 yr $2,217 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,246 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $4,815 if current growth sustains into durable earnings power.
23. PRDO — Perdoceo Education Corporation · score 81.8
Education & Training Services · price $32.03 · 1Y $34.59 · 5Y $43.67 · 10Y $56.01
FCF $225m C · Rev +24.2% A- · D/E 0.12 A- · P/E 12.2x A- · PEG 0.68 A-
Why now. Education & Training Services · market cap $2.0b. 17% off the 52-week high of $38.50. Revenue growing +24%, comfortably above the S&P median. PEG 0.68 — paying under fair value for the growth rate.
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 132% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $34.59 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $43.67 at ~6% CAGR — dividend + buyback compounding. 10 yr $56.01 if the moat survives secular pressure.
24. EPAC — Enerpac Tool Group Corp. · score 79.6
Specialty Industrial Machinery · price $36.60 · 1Y $39.53 · 5Y $49.90 · 10Y $64.00
FCF $111m C · Rev +4.6% C+ · D/E 0.46 B+ · P/E 23.0x B+ · PEG 0.34 A
Why now. Specialty Industrial Machinery · market cap $1.9b. 20% off the 52-week high of $45.54. PEG 0.34 — paying under fair value for the growth rate.
Moat. Net margin 14% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $39.53 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $49.90 at ~6% CAGR — dividend + buyback compounding. 10 yr $64.00 if the moat survives secular pressure.
25. FIVE — Five Below, Inc. · score 78.7
Specialty Retail · price $194.06 · 1Y $260.68 · 5Y $329.10 · 10Y $422.07
FCF $505m C+ · Rev +22.9% A- · D/E 0.86 B · P/E 24.4x B · PEG 0.98 B+
Why now. Specialty Retail · market cap $10.7b. Down 23% from 52-week high of $251.63 — deep drawdown territory. Revenue growing +23%, comfortably above the S&P median. PEG 0.98 — paying under fair value for the growth rate. 22 sell-side analysts rate this a Buy with a mean 1-yr target of $260.68 (implying +34% upside).
Moat. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $260.68 (analyst consensus (n=22)) — multiple re-rating thesis requires a catalyst. 5 yr $329.10 at ~11% CAGR — dividend + buyback compounding. 10 yr $422.07 if the moat survives secular pressure.
26. HURN — Huron Consulting Group Inc. · score 78.2
Consulting Services · price $90.56 · 1Y $184.25 · 5Y $269.76 · 10Y $400.17
1Y -32% D · Rev +11.7% B · ROE 26.1% A- · FCF $124m C
Why now. Consulting Services · market cap $1.5b. Down 52% from 52-week high of $186.78 — deep drawdown territory. Revenue growing +12%, comfortably above the S&P median. 4 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $184.25 (implying +103% upside).
Moat. ROE 26% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 119% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. D/E 2.24 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $184.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $269.76 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $400.17 if current growth sustains into durable earnings power.
27. DV — DoubleVerify Holdings, Inc. · score 78
Advertising Agencies · price $10.33 · 1Y $13.06 · 5Y $19.12 · 10Y $28.36
1Y -29% D · Rev +13.9% B+ · ROE 5.1% C+ · FCF $135m C
Why now. Advertising Agencies · market cap $1.6b. Down 39% from 52-week high of $16.82 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.62 — paying under fair value for the growth rate. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $13.06 (implying +26% upside).
Moat. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk. Down 39% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 31x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. ROE 5% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon. 1-3 yr $13.06 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $19.12 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $28.36 if current growth sustains into durable earnings power.
28. WLDN — Willdan Group, Inc. · score 77.4
Engineering & Construction · price $89.00 · 1Y $96.12 · 5Y $121.35 · 10Y $155.63
FCF $43m C- · Rev +20.5% A- · D/E 0.22 A- · P/E 23.9x B+ · PEG 0.48 A
Why now. Engineering & Construction · market cap $1.3b. Down 35% from 52-week high of $137.00 — deep drawdown territory. Revenue growing +20%, comfortably above the S&P median. PEG 0.48 — paying under fair value for the growth rate.
Moat. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk. Down 35% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $96.12 (structural (no analyst coverage)) — multiple re-rating thesis requires a catalyst. 5 yr $121.35 at ~6% CAGR — dividend + buyback compounding. 10 yr $155.63 if the moat survives secular pressure.
29. DECK — Deckers Outdoor Corporation · score 76.9
Footwear & Accessories · price $109.11 · 1Y $126.86 · 5Y $185.73 · 10Y $275.52
1Y +9% C+ · Rev +9.8% B · ROE 41.0% A · FCF $1.1b C+
Why now. Footwear & Accessories · market cap $15.2b. 14% off the 52-week high of $126.50. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $126.86 (implying +16% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $185.73 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $275.52 if current growth sustains into durable earnings power.
30. NFLX — Netflix, Inc. · score 76.7
Entertainment · price $77.38 · 1Y $114.15 · 5Y $167.12 · 10Y $247.91
1Y -38% D · Rev +15.9% B+ · ROE 43.0% A · FCF $11.9b A-
Why now. Entertainment · market cap $325.8b. Down 42% from 52-week high of $134.12 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 44 sell-side analysts rate this a Buy with a mean 1-yr target of $114.15 (implying +48% upside).
Moat. Net margin 29% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $325.8b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Down 42% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.49 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $114.15 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $167.12 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $247.91 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.